Original Thinking Podcast

Erik Beulen, Professor of Information Management at Alliance Manchester Business School, discusses the challenges around data analytics and digital transformation.

Professor Michelle Carter, Professor of Information Systems at Alliance Manchester Business School, asks whether we are doing enough to ensure AI impacts our lives in truly beneficial ways.

Watch a video of this episode: https://youtu.be/wR6gMBCYWUo

If you're enjoying the Original Thinking Podcast, please leave us a rating or review on whichever platform you're listening on!

Peter Buckley, AMBS's 200th Anniversary Chair in International Business, joins us on our Original Thinking Podcast to talk about the challenges, risks, and future of multinationals.

In our latest Original Thinking filmed podcast Beccy Speight, Chief Executive of the RSPB, joined Professor Paulo Quattrone from Alliance Manchester Business School to discuss how businesses must better encompass Nature in their decision-making and also recognise Nature as an active stakeholder.

In this Original Thinking Podcast, Vlad Jiman, Director of Data at NBrown, discusses how to build a data culture within a large organisation with Professor Panos Constantinides from Alliance Manchester Business School.

What role can corporate sustainability play in terms of business transformation?

Zara De Belder, a recent MBA graduate from Alliance Manchester Business School and sustainability expert, joins Claire Binns, Senior Impact Manager at Sykes Holiday Cottages, to discuss the subject. Claire also talks first-hand about the recent steps Sykes Cottages has taken in terms of its specific approach to measuring and assessing its sustainability credentials.

Three years on from the height of the pandemic this podcast hosted by Alliance Manchester Business School explores the lessons learnt from Protect, a major UK government study into the transmission of the Covid-19 virus and the wider UK research programme around Covid-19.

Debating the findings of the nationwide study are Professor David Fishwick, Chief Medical Advisor at Health and Safety Executive GB, Sheena Johnson, Professor of Work Psychology and Wellbeing at Alliance Manchester Business School, and Martie Van Tongeren, Professor of Occupational and Environmental Health at The University of Manchester.

How do leaders of large organisations and businesses remain agile and nimble when faced with so many day-to-day challenges?

Panos Constantinides, Professor of Digital Innovation at Alliance Manchester Business School, and Simon Hayward, Managing Director and Global Lead for Leadership and Culture at Accenture, discuss how change takes place across organisations, and in particular look at how to embark upon digital transformation.

What does it mean to be truly sustainable and how should companies and organisations approach their Environmental, Social and Governance (ESG) strategies?

These were just some of the key topics explored by Sacha Sadan, Director of ESG at the Financial Conduct Authority, and Professor Konstantinos Stathopoulos from Alliance Manchester Business School, at a podcast hosted by Alliance Manchester Business School.

German biotech firm BioNTech became world famous for developing the mRNA-based Covid vaccine with Pfizer. One of the key figures behind the success was Chief Business and Commercial Officer Sean Marett, who took his MBA at AMBS.

In our latest Original Thinking live podcast, Sean shares the extraordinary story about how the company turned itself on its head from a business developing cancer treatments to one that rapidly began developing a Covid vaccine. He also talks candidly about how the MBA equipped him with crucial skills that he was able to call upon during the Covid crisis.

At our recent Vital Topics lecture Sean admitted that initially his company had no idea if its Covid vaccine was going to work. “We had no idea if anyone was going to buy it even if it worked. We had no supply agreements in place. No global distribution. We had to do all that in 11 months. In the end we actually received approval for the vaccine while we were still scaling up. This meant that 180 countries all wanted our vaccine so we had to decide how to distribute that.”

With the immediate Covid crisis over, the company is now renewing its focus on cancer treatments. For instance, in January this year it signed a Memorandum of Understanding with the UK government to test its different technologies in cancer patients in the UK.